Allergan turns down Valeant

Share this article:

Allergan's board has told Valeant to take its takeover offer elsewhere. Modern Healthcare reports that Allergan's board said the $54 million offer was too low, with too much shareholder risk.

CEO David Pyott told MH the fallout would have probably included a reduced R&D budget, less advertising and higher prices for Allergan products.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.